Transdermal Methylphenidates (Daytrana) for ADHD
A transdermal patch formulation of methylphenidate (Daytrana - Noven/Shire) has been approved by the FDA for treatment of attention-deficit/hyperactivity disorder (ADHD) in patients ≥ 6 years old. Like other methylphenidate products, the patch is a schedule II controlled substance. According to the manufacturer, it will be available in pharmacies by the end of June....
Cannot Access - We are sorry, but you cannot access the requested article.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
Information about the article:
Title: Transdermal Methylphenidates (Daytrana) for ADHD
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 1237
Article Code: 1237a
Date: June 19, 2006
Volume: 48
Pages: 49-51
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 1237
Article Code: 1237a
Date: June 19, 2006
Volume: 48
Pages: 49-51
Subscribe to The Medical Letter on Drugs and Therapeutics for instant access to this article. Add this downloadable, electronic article to your cart (U.S. English version only)